Advice
In the absence of a submission from the holder of the marketing authorisation.
Lanreotide (Samatuline ® LA) is not recommended for use within NHS Scotland for the treatment of thyrotrophic adenomas when the circulating level of thyroid stimulating hormone remains inappropriately high after surgery and/or radiotherapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHS Scotland.
Download detailed advice21KB (PDF)
Medicine details
- Medicine name:
- Lanreotide (Somatuline® LA)
- SMC ID:
- 231/06
- Indication:
- Thyrotrophic adenomas
- Pharmaceutical company
- Ipsen Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 11 December 2006